Human immunodeficiency virus antibodies and the vaccine problem

Journal of Internal Medicine

Volumn 275, Issue 5, 2014, Pages 444-455

  Chiodi, F ^a   Weiss, R A ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody; Envelope glycoprotein; Human immunodeficiency virus; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ANTIVIRAL THERAPY; BINDING SITE; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CONFORMATIONAL TRANSITION; CYTOMEGALOVIRUS; DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; MEMORY CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROTEIN EXPRESSION; REVIEW; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRAL CLEARANCE; VIRUS ATTENUATION; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; VISNA VIRUS;

ANTIBODY; ENVELOPE GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS; VACCINE;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; EPITOPES, B-LYMPHOCYTE; FORECASTING; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; TECHNOLOGY, PHARMACEUTICAL; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 84898678991     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12225     Document Type: Review

References (77)

1. Plotkin S, Orenstein W, Offit PA. Vaccines 2012; Expert Consult Basic Books.
2. Koff WC, Burton DR, Johnson PR et al. Accelerating next-generation vaccine development for global disease prevention. Science 2013; 340: 1064-71.
3. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012; 30: 4301-6.
4. Poignard P, Sabbe R, Picchio PR et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10: 431-8.
5. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013; 31: 705-42.
6. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009; 4: 388-93.
7. Hayes P, Gilmour J, von Lieven A et al. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults. Clin Vaccine Immunol 2013; 20: 397-408.
8. Hansen SG, Piatak M Jr, Ventura AB et al. Immune clearance of highly pathogenic SIV infection. Nature 2013; 502: 100-4.
9. Schiffner T, Kong L, Duncan CJ et al. Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. J Virol 2013; 87: 10163-72.
10. Rappuoli R. Vaccine adjuvants: the future is bright. Expert Rev Vaccines 2013; 12: 727-9.
11. Harandi AM, Medaglini D, Shattock RJ, Working Group convened by EUROPRISE. Vaccine adjuvants: a priority for vaccine research. Vaccine 2010; 28: 2363-6.
12. Whitney JB, Ruprecht RM. Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 2004; 17: 17-26.
13. Forsman A, Weiss RA. Why is HIV a pathogen? Trends Microbiol 2008; 16: 555-60.
14. Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 2009; 6: 51.
15. Reina R, Berriatua E, Luján L et al. Prevention strategies against small ruminant lentiviruses: an update. Vet J 2009; 182: 313-7.
16. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011; 1: a006841.
17. Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5: 204-10.
18. Hessell AJ, Rakasz EG, Poignard P et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5: e1000433.
19. Watkins JD, Sholukh AM, Mukhtar MM et al. Anti-HIV isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 2013; 27: F13-20.
20. Baroncelli S, Negri DR, Michelini Z, Cara A. Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development. Expert Rev Vaccines 2008; 7: 1419-34.
21. Fujita Y, Taguchi H. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines. Ther Deliv 2012; 3: 749-60.
22. Leung CS, Chijioke O, Gujer C et al. Infectious diseases in humanized mice. Eur J Immunol 2013; 43: 2246-54.
23. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2011; 481: 81-4.
24. Ndung'u T, Weiss RA. On HIV diversity. AIDS 2012; 26: 1255-60.
25. Aasa-Chapman MM, Holuigue S, Aubin K et al. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 2005; 79: 2823-30.
26. Burton DR, Ahmed R, Barouch DH et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012; 12: 396-407.
27. Kwong PD, Doyle ML, Casper DJ et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420: 678-82.
28. Schiffner T, Sattentau QJ, Dorrell L. Development of prophylactic vaccines against HIV-1. Retrovirology 2013; 10: 72.
29. Overbaugh J, Morris L. The antibody response against HIV-1. Cold Spring Harb Perspect Med 2012; 2: a007039.
30. Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-12.
31. Parrish NF, Gao F, Li H et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA 2013; 110: 6626-33.
32. McCoy LE, Quigley AF, Strokappe NM et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med 2012; 209: 1091-103.
33. Kwong PD, Mascola JR, Nabel GJ. The changing face of HIV vaccine research. J Int AIDS Soc 2012; 15: 17407.
34. Julien JP, Lee JH, Cupo A et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA 2013; 110: 4351-6.
35. Julien JP, Sok D, Khayat R et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 2013; 9: e1003342.
36. Scheid JF, Mouquet H, Ueberheide B et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333: 1633-7.
37. Corti D, Langedijk JP, Hinz A et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010; 5: e8805.
38. Huang J, Ofek G, Laub L et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012; 491: 406-12.
39. Walker LM, Phogat SK, Chan-Hui PY et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326: 285-9.
40. McCoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 2013; 210: 209-23.
41. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903-15.
42. Amu S, Ruffin N, Rethi B, Chiodi F. Impairment of B-cell functions during HIV-1 infection. AIDS 2013; 27: 2323-34.
43. Titanji K, De Milito A, Cagigi A et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006; 108: 1580-7.
44. Pensieroso S, Cagigi A, Palma P et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci USA 2009; 106: 7939-44.
45. Moir S, Ho J, Malaspina A et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008; 205: 1797-805.
46. Kardava L, Moir S, Wang W et al. Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J Clin Invest 2011; 121: 2614-24.
47. Huang KH, Bonsall D, Katzourakis A et al. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun 2010; 1: 102.
48. Pan-Hammarstrom Q, Zhao Y, Hammarstrom L. Class switch recombination: a comparison between mouse and human. Adv Immunol 2007; 93: 1-61.
49. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Antibodies in HIV-1 vaccine development and therapy. Science 2013; 341: 1199-204.
50. Titanji K, Velu V, Chennareddi L et al. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J Clin Invest 2010; 120: 3878-90.
51. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195-201. Review
52. Horwitz JA, Halper-Stromberg A, Mouquet H et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci USA 2013; 110: 16538-43.
53. Reyes-del Valle J, de la Fuente C, Turner MA et al. Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol 2012; 86: 11558-66.
54. Nabel GJ. Designing tomorrow's vaccines. N Engl J Med 2013; 368: 551-60.
55. Wu X, Yang ZY, Li Y et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329: 856-61.
56. Cohen J. Structural biology. Is high-tech view of HIV too good to be true? Science 2013; 341: 443-4.
57. Julien JP, Cupo A, Sok D et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013; 342: 1477-83.
58. Bonsignori M, Hwang KK, Chen X et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011; 85: 9998-10009.
59. Lutje Hulsik D, Liu YY, Strokappe NM et al. A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition. PLoS Pathog 2013; 9: e1003202.
60. McGuire AT, Hoot S, Dreyer AM et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 2013; 210: 655-63.
61. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-20.
62. Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366: 1275-86.
63. Willey S, Aasa-Chapman MM. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol 2008; 16: 596-604.
64. Gorlani A, Forthal DN. Antibody-dependent enhancement and the risk of HIV infection. Curr HIV Res 2013; 11: 421-6.
65. Willey S, Aasa-Chapman MM, O'Farrell S et al. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology 2011; 8: 16.
66. Broliden K, Hinkula J, Devito C et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001; 79: 29-36.
67. Hirbod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J Intern Med 2007; 262: 44-58.
68. Tudor D, Derrien M, Diomede L et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009; 2: 412-26.
69. Tudor D, Yu H, Maupetit J et al. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci USA 2012; 109: 12680-5.
70. Shimizu S, Rao DS, Gnanapragasam PN, An DS, Yang L, Baltimore D. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 2012; 120: 4571-82.
71. Hur EM, Patel SN, Klein F et al. Antibodies in HIV-1 vaccine development and therapy. Science 2013; 341: 1199-204.
72. Ross AL, Bråve A, Scarlatti G, Manrique A, Buonaguro L. Antibodies in HIV-1 vaccine development and therapy. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis, 2010; 10: 305-16.
73. Lagenaur LA, Sanders-Beer BE, Brichacek B et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 2011; 4: 648-57.
74. Gorlani A, Brouwers J, McConville C et al. Llama antibody fragments have good potential for application as HIV type 1 topical microbicides. AIDS Res Hum Retroviruses 2012; 28: 198-205.
75. Barouch DH, Whitney JB, Moldt B et al. Therapeutic efficacy of potent neutralizing HIV specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503: 224-8.
76. Shingai M, Nishimura Y, Klein F et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503: 277-80.
77. Balasz AP, West AB. Antibody gene transfer for HIV immunoprophylaxis. Nat Immunol 2013; 14: 1-5.